Can a Hippo Save the IPO Market for Life Sciences?
This article was originally published in Start Up
Executive Summary
A group of private enterprises are working to revive the moribund IPO market for venture-backed start-ups.
You may also be interested in...
What Happens After the Device IPO?
Investors love to remind everyone that IPOs are financing events, not exiting events, using the mantra to put off Judgment Day for their investments. So how have device companies fared after the recent spate of IPOs?
IPO Failures Can Set Up Biotech Successes
Did the 31 biotechs who pulled IPOs since 2003 destroy value? By and large, no-thanks to a growing variety of financing and exit options, most thanks to Pharma's increasing appetite for high-value deals and deeper private equity pockets.
IPO Device Window Threatened by Valuation Declines
The recent market declines that have driven down the valuations of newly-public medical technology companies have sent shudders through the device start-up community.